Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
Invivyd announced the completion of enrollment in its DECLARATION Phase 3 pivotal trial for VYD2311, a monoclonal antibody candidate for COVID-19 prevention. The trial was upsized by approximately 500 subjects following a pre-specified sample size re-estimation analysis to ensure statistical robustness against variable COVID event rates.
Key figures
- Drug Name
- VYD2311
- Phase Of Trial
- Phase 3
- Total enrollment
- 2400
- Expected results date
- late Q3 2026
- Additional subjects added
- 500
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.